Lunai Bioworks secures LOI for tumor-regressing immune-cell therapy platform.

Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models. The therapy uses AI-powered drug discovery and biodefense to target aggressive cancers. This milestone follows Lunai's recent peer-reviewed publication and successful pre-IND meeting with the FDA.